-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on August 13 As the epidemic prevention and control has become normal, citizens’ daily lives have gradually returned to normal tracks.
The “eating and drinking” model has led to a rapid recovery of the domestic economy and the health care product market.
The good news: "Big Brother" Tomson Beijian recently released the first half of 2021 performance.
The company achieved operating income of 4.
198 billion yuan and net profit of 1.
371 billion yuan, both of which set new records
.
Figure 1: The performance of BY-HEALTH in the past three years (unit: 100 million yuan) Source: The company's semi-annual report, BY-HEALTH, out of the haze of the epidemic, achieved the best record in both revenue and net profit in the first half of this year, with a year-on-year increase Respectively reached 34.
32% and 42.
55%
.
In terms of different channels, offline channels still dominate, accounting for approximately 71.
71% of domestic revenue, a year-on-year increase of 24.
18%.
With the rapid development of e-commerce, online channel revenue increased by 79.
72% year-on-year
.
It is reported that the company's domestic offline channels mainly include regional distribution models and direct supply models.
For some of the top 100 chain pharmacies and supermarkets and other important retail terminals, the company adopts the direct supply model to establish business partnerships with them
.
In response to investors’ questions, BY-HEALTH mentioned that the cost of offline channels is much lower than that of online channels, while the pharmacy channel has a traffic advantage.
The company is making every effort to build its brand and empower retail terminals for sales conversion
.
Table 1: By-Health’s market share of TOP10 products in physical pharmacies in cities in China Source: Menet.
com Data from Chinese city physical pharmacies on Minet.
com shows that in the past three years, multiple products of By-Health have been obtained in physical pharmacies in cities in China.
Leading position, the company’s over 1 billion variety Jianliduo (Glucosamine Chondroitin calcium tablets) has accounted for more than 60% of the market for increasing bone density.
It is reported that the revenue of this product has also increased by 29.
25% in the first half of this year.
Chen Beijian stated that the company will continue to consolidate its leading position in the category through the expansion of consumer groups and consumption scenarios, channel penetration, etc.
.
Another single product of the company that has a leading market position is Health Vision (Bilberry Lutein Beta-Carotene Soft Capsules), which will occupy 43.
11% of the market for asthenopia relief in 2020.
By-Health said that at present The product is expanding from regional promotion to national promotion, and it is expected to continue to expand its leadership in the future
.
BY-HEALTH formulated a large single product strategy in 2017.
The company plans to launch a 1 billion-level single product every 2 to 3 years.
Through the rapid growth of large single products, it will drive the growth of the main brand
.
At present, the company’s four main single products, Jianli Duo and Jianshijia, have achieved good results.
Jiananshi (Silybum marianum and Pueraria lobata Danshen tablets) ranks TOP3 in the auxiliary protection category against chemical liver injury.
In 2020, its market share in this category has risen to 19.
99%, and the company said it is focusing on building a core model market
.
Aiming at the new generation of plant technology-assisted blood lipid-lowering product Shubaining (Natto Red Yeast Capsules), the company will also adopt a new drug-like marketing model
.
For some of the company’s old products, such as the "multivitamin" series, precision marketing will be used to enhance the brand's voice and consolidate the market position; increase the star product "colostrum plus calcium chewable tablets" and enrich the children's full product matrix, driving the children's series Growth; "Melatonin" drives market segment business growth by accurately positioning market demand
.
With the rapid development of e-commerce, the industry is also very concerned about BY-HEALTH’s channel organization
.
The company mentioned in the semi-annual report that starting from July 2021, the company has officially launched offline sales reforms and online and offline integrated operation related reforms to support the company's healthier and sustainable development strategy, which is expected to continue until 2022 The first half of the year
.
Source: the company's annual report, Minet.
com database Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the city entity that covers 293 prefectures and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors the entire category Pharmacy database
.
The above sales are calculated based on the average retail price of the product at the terminal
.
The “eating and drinking” model has led to a rapid recovery of the domestic economy and the health care product market.
The good news: "Big Brother" Tomson Beijian recently released the first half of 2021 performance.
The company achieved operating income of 4.
198 billion yuan and net profit of 1.
371 billion yuan, both of which set new records
.
Figure 1: The performance of BY-HEALTH in the past three years (unit: 100 million yuan) Source: The company's semi-annual report, BY-HEALTH, out of the haze of the epidemic, achieved the best record in both revenue and net profit in the first half of this year, with a year-on-year increase Respectively reached 34.
32% and 42.
55%
.
In terms of different channels, offline channels still dominate, accounting for approximately 71.
71% of domestic revenue, a year-on-year increase of 24.
18%.
With the rapid development of e-commerce, online channel revenue increased by 79.
72% year-on-year
.
It is reported that the company's domestic offline channels mainly include regional distribution models and direct supply models.
For some of the top 100 chain pharmacies and supermarkets and other important retail terminals, the company adopts the direct supply model to establish business partnerships with them
.
In response to investors’ questions, BY-HEALTH mentioned that the cost of offline channels is much lower than that of online channels, while the pharmacy channel has a traffic advantage.
The company is making every effort to build its brand and empower retail terminals for sales conversion
.
Table 1: By-Health’s market share of TOP10 products in physical pharmacies in cities in China Source: Menet.
com Data from Chinese city physical pharmacies on Minet.
com shows that in the past three years, multiple products of By-Health have been obtained in physical pharmacies in cities in China.
Leading position, the company’s over 1 billion variety Jianliduo (Glucosamine Chondroitin calcium tablets) has accounted for more than 60% of the market for increasing bone density.
It is reported that the revenue of this product has also increased by 29.
25% in the first half of this year.
Chen Beijian stated that the company will continue to consolidate its leading position in the category through the expansion of consumer groups and consumption scenarios, channel penetration, etc.
.
Another single product of the company that has a leading market position is Health Vision (Bilberry Lutein Beta-Carotene Soft Capsules), which will occupy 43.
11% of the market for asthenopia relief in 2020.
By-Health said that at present The product is expanding from regional promotion to national promotion, and it is expected to continue to expand its leadership in the future
.
BY-HEALTH formulated a large single product strategy in 2017.
The company plans to launch a 1 billion-level single product every 2 to 3 years.
Through the rapid growth of large single products, it will drive the growth of the main brand
.
At present, the company’s four main single products, Jianli Duo and Jianshijia, have achieved good results.
Jiananshi (Silybum marianum and Pueraria lobata Danshen tablets) ranks TOP3 in the auxiliary protection category against chemical liver injury.
In 2020, its market share in this category has risen to 19.
99%, and the company said it is focusing on building a core model market
.
Aiming at the new generation of plant technology-assisted blood lipid-lowering product Shubaining (Natto Red Yeast Capsules), the company will also adopt a new drug-like marketing model
.
For some of the company’s old products, such as the "multivitamin" series, precision marketing will be used to enhance the brand's voice and consolidate the market position; increase the star product "colostrum plus calcium chewable tablets" and enrich the children's full product matrix, driving the children's series Growth; "Melatonin" drives market segment business growth by accurately positioning market demand
.
With the rapid development of e-commerce, the industry is also very concerned about BY-HEALTH’s channel organization
.
The company mentioned in the semi-annual report that starting from July 2021, the company has officially launched offline sales reforms and online and offline integrated operation related reforms to support the company's healthier and sustainable development strategy, which is expected to continue until 2022 The first half of the year
.
Source: the company's annual report, Minet.
com database Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the city entity that covers 293 prefectures and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors the entire category Pharmacy database
.
The above sales are calculated based on the average retail price of the product at the terminal
.
